CSL Limited (CMXHF) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Melbourne, VIC, オーストラリア. 現CEOは Gordon Naylor DipCompSc.
CMXHF を有する IPO日 2005-11-18, 32,698 名の正社員, に上場 Other OTC, 時価総額 $46.93B.
CSL Limited is a global biopharmaceutical company founded in 1916 and headquartered in Parkville, Australia. The company researches, develops, manufactures, and distributes biopharmaceutical products across Australia, the United States, Europe, China, and other international markets. Operating through two main divisions—CSL Behring and Seqirus—the company specializes in plasma-derived therapies for immunodeficiency, bleeding disorders, and neurological conditions, as well as non-plasma biotherapeutics and influenza-related products. CSL Behring also generates revenue through licensing and royalties on intellectual property commercialization.